OUR LATEST LINKEDIN UPDATES
You are currently viewing a placeholder content from SociableKIT LinkedIn Feed. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationLATEST RESOURCES FOR DOWNLOAD
LATEST EXPERT VIDEOS
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information
Jorge Castillo discusses the relative efficacy and safety of BTK inhibitors with or without BCL2 inhibitors in Waldenström’s macroglobulinemia (WM), highlights important prognostic molecular markers in untreated patients, and reveals new insights into the biology of the disease. He also explores novel therapeutic targets that may shape the future of WM treatment.